Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: NEURON

University of Toronto

$225,000.00

Treating inherited blinding disease with a slow released form of the rod-derived cone viability factor protein

FY 2020-21

Summary
Vision relies on two types of photoreceptors in the retina at the back of the eye: rod photoreceptors, which are responsible for night vision, and cone photoreceptors, which are responsible for daylight vision. Rods and cones have an intimate relationship, with rod photoreceptors producing a factor, rod-derived cone viability factor (RdCVF), which is critical to cone viability. When rod photoreceptors die, cone photoreceptors die and all vision is lost; however, if we could find a way to preserve cone photoreceptors, then we could overcome vision loss associated with blinding diseases. Geneticists have shown that one of the most common forms of inherited blinding diseases is caused by mutations in large numbers of genes, some of which are only active in rod photoreceptors. The death of these rods results in the loss of a protein, rod-derived cone viability factor (RdCVF), which then results in the loss of cone photoreceptors and ultimately blindness. In order to stop the progression of this disease, we propose to save cone photoreceptors, and hence daylight vision, by replacing the lost RdCVF with newly delivered RdCVF. Specifically, we propose to deliver a novel slow-release formulation of RdCVF directly to the eyes of patients using a strategy already shown to be safe for patients with age-related macular degeneration. We will study the benefit of our treatment strategy in three models of blinding diseases, starting from the mouse and rat to a novel model in a minipig, a species in which the eyes are similar those of humans. DrEYE is a preclinical study of an innovative treatment that, with success, will restore vision to the two million patients worldwide suffering from inherited blinding diseases and for which there are no other options.
Program
Team Grant: NEURON
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
431268
Name
Shoichet Molly S
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
German Federal Ministry of Research, Technology and Space (Berlin); Israeli Ministry of Health; The French National Research Agency (France)
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Treating inherited blinding disease with a slow released form of the rod-derived cone viability factor protein
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$225,000
Cihrequipment2
$0
Programname2
Team Grant: NEURON
Keyworddelim
Affinity Controlled Release; Blindness; Hydrogel; Inherited Retinal Disease; Local Delivery; Rod-Derived Cone Viability Factor; Vision Repair
Abstract
Vision relies on two types of photoreceptors in the retina at the back of the eye: rod photoreceptors, which are responsible for night vision, and cone photoreceptors, which are responsible for daylight vision. Rods and cones have an intimate relationship, with rod photoreceptors producing a factor, rod-derived cone viability factor (RdCVF), which is critical to cone viability. When rod photoreceptors die, cone photoreceptors die and all vision is lost; however, if we could find a way to preserve cone photoreceptors, then we could overcome vision loss associated with blinding diseases. Geneticists have shown that one of the most common forms of inherited blinding diseases is caused by mutations in large numbers of genes, some of which are only active in rod photoreceptors. The death of these rods results in the loss of a protein, rod-derived cone viability factor (RdCVF), which then results in the loss of cone photoreceptors and ultimately blindness. In order to stop the progression of this disease, we propose to save cone photoreceptors, and hence daylight vision, by replacing the lost RdCVF with newly delivered RdCVF. Specifically, we propose to deliver a novel slow-release formulation of RdCVF directly to the eyes of patients using a strategy already shown to be safe for patients with age-related macular degeneration. We will study the benefit of our treatment strategy in three models of blinding diseases, starting from the mouse and rat to a novel model in a minipig, a species in which the eyes are similar those of humans. DrEYE is a preclinical study of an innovative treatment that, with success, will restore vision to the two million patients worldwide suffering from inherited blinding diseases and for which there are no other options.
Competitiondate
202006
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Shoichet, Molly S
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $225,000~ $0~
University of Toronto - $225,000 Grant (2020-21) | Canada Spends